Uprosertib

Drug Profile

Uprosertib

Alternative Names: GSK-2141795; GSK-2141795C; GSK-795

Latest Information Update: 17 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Dana-Farber Cancer Institute; GlaxoSmithKline; National Cancer Institute (USA); National Comprehensive Cancer Network; University of California at San Francisco
  • Class Amides; Antineoplastics; Furans; Pyrazoles; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Breast cancer; Cervical cancer; Endometrial cancer; Malignant melanoma; Multiple myeloma; Uveal melanoma
  • No development reported Lymphoma; Ovarian cancer; Solid tumours

Most Recent Events

  • 10 Aug 2016 Novartis terminates a phase II trial in Cervical cancer (Combination therapy, Recurrent) in USA due to reasons related to drug supply (NCT01958112)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Monotherapy) in Canada (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Monotherapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top